[go: up one dir, main page]

MX2007007033A - Estreptococus del grupo b. - Google Patents

Estreptococus del grupo b.

Info

Publication number
MX2007007033A
MX2007007033A MX2007007033A MX2007007033A MX2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A
Authority
MX
Mexico
Prior art keywords
streptococcus
group
vaccines
antibiotics
polypeptides
Prior art date
Application number
MX2007007033A
Other languages
English (en)
Inventor
Vega Masignani
Herve Tettelin
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MX2007007033A publication Critical patent/MX2007007033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los polipeptidos y acidos nucleicos de Streptococcus agalactiae, que pueden ser utilizados en el desarrollo de vacunas, para fines de diagnostico, y como objetivos para antibioticos.
MX2007007033A 2004-12-22 2005-12-21 Estreptococus del grupo b. MX2007007033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63894304P 2004-12-22 2004-12-22
US64043804P 2004-12-30 2004-12-30
PCT/US2005/046491 WO2006069200A2 (en) 2004-12-22 2005-12-21 Group b streptococcus

Publications (1)

Publication Number Publication Date
MX2007007033A true MX2007007033A (es) 2007-08-03

Family

ID=36602309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007033A MX2007007033A (es) 2004-12-22 2005-12-21 Estreptococus del grupo b.

Country Status (8)

Country Link
US (1) US20090104218A1 (es)
EP (1) EP1828231A2 (es)
JP (1) JP2008525033A (es)
AU (1) AU2005319174A1 (es)
CA (1) CA2591510A1 (es)
IL (1) IL183830A0 (es)
MX (1) MX2007007033A (es)
WO (1) WO2006069200A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535122A (en) 1998-12-22 2006-04-28 Microscience Ltd Gene and proteins, and their use
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
EP1801235A1 (en) 2005-12-20 2007-06-27 Institut Pasteur Rapid detection of the "high virulent" ST-17 clone of Group B streptococcus
WO2008020308A2 (en) * 2006-06-19 2008-02-21 Mutabilis Sa Identification of genes implicated in the virulence of streptococcus agalactiae
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
EP2135877A1 (en) 2008-06-19 2009-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Marker of steptococcus anginosus/Streptococcus constellatus (Moac) and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
MX2012000158A (es) 2009-06-29 2012-06-08 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN105833260A (zh) 2011-01-20 2016-08-10 健诺西生物科学公司 针对肺炎链球菌（Streptococcus Pneumoniae）的疫苗和组合物
JP5986931B2 (ja) * 2011-02-02 2016-09-06 公益財団法人微生物化学研究会 血液脳関門を透過する薬物輸送体、ペプチド及びその用途
EP2557424A1 (en) * 2011-08-11 2013-02-13 InGen Biosciences Method for diagnosing Streptococcus, Enterococcus and Pepstostreptococcus genera infections
US20150273042A1 (en) * 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
RU2636466C2 (ru) * 2012-03-30 2017-11-23 Е.И.Дюпон Де Немур Энд Компани Получение перкислот и композиции с использованием фермента, обладающего пергидролитической активностью
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
WO2015008214A1 (en) * 2013-07-16 2015-01-22 Universite De Lausanne Bacterial lysins and uses thereof
BE1022792B1 (fr) * 2014-08-05 2016-09-06 Glaxosmithkline Biologicals S.A. Molecule support
WO2017134274A1 (en) 2016-02-04 2017-08-10 Ulrich Von Pawel-Rammingen New streptococcal proteases
WO2018204153A1 (en) * 2017-05-02 2018-11-08 Venomyx, Inc. Composition and methods for treating snake envenomation
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
PL239045B1 (pl) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitop specyficzny dla zakaźnych Streptococcus agalactiae oraz sposób wykrywania zakażenia pacjenta szczepem Streptococcus agalactiae
CN112654721B (zh) * 2018-06-13 2025-01-07 简·探针公司 用于检测b群链球菌核酸的组合物和方法
CA3108865A1 (en) 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
AU2020395148A1 (en) * 2019-12-06 2022-06-23 Theratechnologies Inc. Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
KR20220139918A (ko) 2020-02-03 2022-10-17 메디카인 인코포레이티드 IL-7Rαγc 결합 화합물
US20230127948A1 (en) * 2020-02-12 2023-04-27 The Broad Institute, Inc. Field deployable crispr-cas diagnostics and methods of use thereof
US11453907B2 (en) 2020-03-23 2022-09-27 The Broad Institute, Inc. Crispr effector system based coronavirus diagnostics
WO2022026534A1 (en) * 2020-07-28 2022-02-03 Kansas State University Research Foundation Sars-cov-2 immunogenic compositions and methods for protecting against sars-cov-2 clinical signs
AU2021376351A1 (en) * 2020-11-04 2023-06-08 Medikine, Inc. IL-2Rβγc BINDING COMPOUNDS AND USES THEREOF
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2025017062A1 (en) * 2023-07-18 2025-01-23 Intervet International B.V. New type of streptococcus agalactiae serotype ia bacterium and vaccines thereof
WO2025151408A1 (en) * 2024-01-08 2025-07-17 Denali Therapeutics Inc. Compositions and methods for modulating tau expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
JP2002531054A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド Ｂ群連鎖球菌由来の核酸およびタンパク質
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
US7485710B2 (en) * 2002-10-15 2009-02-03 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
CA2591510A1 (en) 2006-06-29
EP1828231A2 (en) 2007-09-05
US20090104218A1 (en) 2009-04-23
WO2006069200A3 (en) 2007-03-01
AU2005319174A1 (en) 2006-06-29
WO2006069200A2 (en) 2006-06-29
JP2008525033A (ja) 2008-07-17
IL183830A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
MX2007007033A (es) Estreptococus del grupo b.
MY154904A (en) Neuropilin antagonists
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
EA201301072A1 (ru) Антитела против il-23p19 и их применение
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EP4435100A3 (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2007117763A3 (en) Methods and compositions for targeting relt
WO2009050277A3 (en) Edta resistant s100a12 complexes (erac)
WO2008054595A3 (en) Drug controlled molecular tags
WO2003093298A3 (en) Immunogenic peptides
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
WO2006047728A3 (en) Bmp gene and fusion protein
GB0818080D0 (en) Immunogenic peptides
WO2010110931A3 (en) Glycoconjugate vaccines
WO2007102946A3 (en) Crystalline polypeptides
WO2006089209A3 (en) Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2007077464A3 (en) Chicken virus vaccine and diagnostic
PL1951738T3 (pl) Nowe formy krystaliczne rostafuroksyny
WO2006104761A3 (en) Unique sequence hybridization probes (usp)
WO2006122277A3 (en) Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: J. CRAIG VENTER INSTITUTE, INC.

FA Abandonment or withdrawal